Last 7 days
-1.0%
Last 30 days
-3.3%
Last 90 days
-3.4%
Trailing 12 Months
22.3%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-09-12 | Parsey Merdad | sold | -115,562 | 76.99 | -1,501 | chief medical officer |
2023-09-10 | Patterson Sandra | acquired | - | - | 519 | svp, controllership |
2023-09-10 | Parsey Merdad | sold (taxes) | -97,128 | 76.00 | -1,278 | chief medical officer |
2023-09-10 | Mercier Johanna | sold (taxes) | -95,456 | 76.00 | -1,256 | chief commercial officer |
2023-09-10 | O'Day Daniel Patrick | acquired | - | - | 7,348 | chairman & ceo |
2023-09-10 | Patterson Sandra | sold (taxes) | -11,324 | 76.00 | -149 | svp, controllership |
2023-09-10 | Dickinson Andrew D | acquired | - | - | 2,619 | chief financial officer |
2023-09-10 | Mercier Johanna | acquired | - | - | 2,730 | chief commercial officer |
2023-09-10 | O'Day Daniel Patrick | sold (taxes) | -255,816 | 76.00 | -3,366 | chairman & ceo |
2023-09-10 | Parsey Merdad | acquired | - | - | 2,779 | chief medical officer |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-10-02 | PARK NATIONAL CORP /OH/ | added | 22.51 | 49,240 | 306,654 | 0.01% |
2023-09-26 | M Holdings Securities, Inc. | sold off | -100 | -726,000 | - | -% |
2023-09-26 | BROOKFIELD Corp /ON/ | reduced | -92.45 | -2,694,740 | 203,234 | -% |
2023-09-21 | Baystate Wealth Management LLC | added | 17.83 | 2,775 | 32,616 | -% |
2023-09-21 | Jefferies Group LLC | new | - | 2,313,740 | 2,313,740 | 0.02% |
2023-09-20 | Mondrian Investment Partners LTD | unchanged | - | -17,853 | 233,214 | -% |
2023-09-20 | BARCLAYS PLC | added | 47.07 | 137,216,000 | 511,970,000 | 0.32% |
2023-09-14 | IMS Capital Management | unchanged | - | -28,987 | 378,645 | 0.21% |
2023-09-12 | Farther Finance Advisors, LLC | added | 3.14 | -22,010 | 503,190 | 0.11% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | added | 13.72 | 14,280 | 267,587 | 0.08% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | capital research global investors | 4.4% | 54,602,952 | SC 13G/A | |
Feb 13, 2023 | capital world investors | 5.5% | 68,900,998 | SC 13G | |
Feb 09, 2023 | vanguard group inc | 8.93% | 112,038,324 | SC 13G/A | |
Jan 31, 2023 | blackrock inc. | 10.5% | 131,555,769 | SC 13G/A | |
Jul 08, 2022 | blackrock inc. | 10.1% | 126,932,693 | SC 13G | |
Feb 11, 2022 | capital research global investors | 8.5% | 107,156,981 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 8.43% | 105,803,799 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 9.5% | 118,961,206 | SC 13G/A | |
Feb 16, 2021 | capital research global investors | 9.7% | 121,672,399 | SC 13G/A | |
Feb 16, 2021 | capital research global investors | 9.7% | 121,672,399 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 29, 2023 | 4 | Insider Trading | |
Sep 14, 2023 | 8-K | Current Report | |
Sep 13, 2023 | 4 | Insider Trading | |
Sep 12, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 11, 2023 | 4 | Insider Trading | |
Sep 11, 2023 | 4 | Insider Trading | |
Sep 11, 2023 | 4 | Insider Trading | |
Sep 11, 2023 | 4 | Insider Trading | |
Sep 11, 2023 | 4 | Insider Trading | |
Sep 11, 2023 | 424B5 | Prospectus Filed |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 142.4B | 26.6B | 3.74% | 20.01% | 17.85 | 5.36 | 0.75% | 21.34% |
GILD | 92.4B | 27.4B | -3.33% | 22.27% | 16.85 | 3.37 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -8.22% | -12.63% | 32.61 | 3.69 | -53.67% | -91.41% |
BIIB | 36.6B | 10.0B | -5.36% | -5.30% | 13.73 | 3.67 | -6.23% | 29.40% |
MID-CAP | ||||||||
NBIX | 10.9B | 1.7B | 1.05% | 5.25% | 61.85 | 6.52 | 29.01% | 1345.90% |
BBIO | 4.1B | - | -16.91% | 155.63% | -7.02 | 48.33 | 54.84% | -12.96% |
DNLI | 2.7B | - | -15.10% | -35.52% | -21.18 | 37.44 | 122.90% | 54.78% |
BEAM | 1.7B | 80.2M | -8.35% | -54.87% | -5.12 | 20.91 | 42.17% | -39.82% |
SMALL-CAP | ||||||||
RCUS | 1.3B | 121.2M | -18.44% | -33.91% | -4.48 | 10.62 | -70.36% | -531.73% |
REPL | 931.2M | 15.3M | -19.93% | -8.57% | -5.13 | 60.82 | 1090.59% | -36.57% |
NVAX | 668.6M | 1.6B | -13.64% | -61.04% | -1.14 | 0.42 | 23.74% | 60.24% |
FATE | 189.2M | - | -31.67% | -91.43% | -0.89 | 1.38 | 116.83% | 16.61% |
VXRT | 113.0M | 2.1M | -10.53% | -65.89% | -1.12 | 55 | 487.70% | -8.66% |
SGMO | 104.6M | - | -38.94% | -87.76% | -0.53 | 0.43 | 113.96% | -15.19% |
IBIO | 6.3M | - | 5.48% | -92.77% | -0.08 | 3.21 | - | -129.46% |
4.4%
2.7%
2.4%
9.9%
41.9%
0%
0%
Y-axis is the maximum loss one would have experienced if Gilead Sciences was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | 1.3% | 27,382 | 27,043 | 27,281 | 27,136 | 27,515 | 27,472 | 27,305 | 27,482 | 26,638 | 25,564 | 24,689 | 23,147 | 22,174 | 22,716 | 22,449 | 22,365 | 22,357 | 22,320 | 22,127 | 22,281 | 23,197 |
Costs and Expenses | 3.9% | 18,908 | 18,205 | 19,951 | 21,133 | 20,507 | 20,247 | 17,387 | 15,853 | 16,850 | 21,005 | 20,618 | 20,634 | 23,135 | 18,264 | 18,162 | 18,027 | 13,923 | 14,036 | 13,927 | 12,934 | 12,661 |
S&GA Expenses | 8.3% | 6,401 | 5,909 | 5,673 | 5,303 | 5,280 | 5,274 | 5,246 | 5,326 | 5,242 | 5,130 | 5,151 | 4,625 | 4,571 | 4,427 | 4,381 | 4,308 | 4,204 | 4,089 | 4,056 | 4,177 | 4,108 |
R&D Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9,150 | 9,106 | 9,157 | 5,106 | 5,138 | 5,018 | 3,290 | 3,140 |
EBITDA | -100.0% | - | 8,530 | 7,072 | 5,819 | 6,848 | 7,175 | 9,608 | 10,681 | 8,045 | 2,930 | 2,653 | 2,716 | 404 | 5,795 | 6,155 | - | - | - | - | - | - |
EBITDA Margin | -100.0% | - | 0.32* | 0.26* | 0.21* | 0.25* | 0.26* | 0.35* | 0.39* | 0.30* | 0.11* | 0.11* | 0.12* | 0.02* | 0.26* | 0.27* | - | - | - | - | - | - |
Interest Expenses | -1.3% | 915 | 927 | 935 | 947 | 968 | 982 | 1,001 | 1,030 | 1,016 | 1,000 | 984 | 960 | 974 | 982 | 995 | 1,009 | 1,023 | 1,041 | 1,077 | 1,117 | 1,144 |
Earnings Before Taxes | 1.2% | 7,351 | 7,266 | 5,814 | 4,542 | 5,548 | 5,862 | 8,278 | 9,333 | 6,720 | 1,930 | 1,669 | 1,756 | -570 | 4,813 | 5,160 | 4,275 | 8,440 | 8,116 | 7,799 | 8,909 | 9,916 |
EBT Margin | -100.0% | - | 0.27* | 0.21* | 0.17* | 0.20* | 0.21* | 0.30* | 0.34* | 0.25* | 0.08* | 0.07* | 0.08* | -0.03* | 0.21* | 0.23* | - | - | - | - | - | - |
Net Income | -1.8% | 5,484 | 5,583 | 4,592 | 3,334 | 4,137 | 4,515 | 6,225 | 7,394 | 5,162 | 301 | 123 | 1,268 | -257 | 4,962 | 5,386 | 2,693 | 5,955 | 5,892 | 5,455 | 1,587 | 2,208 |
Net Income Margin | -100.0% | - | 0.21* | 0.17* | 0.12* | 0.15* | 0.16* | 0.23* | 0.27* | 0.19* | 0.01* | 0.00* | 0.05* | -0.01* | 0.22* | 0.24* | - | - | - | - | - | - |
Free Cashflow | -100.0% | - | 8,386 | 8,344 | 9,007 | 9,415 | 9,953 | 10,805 | 9,491 | 8,472 | 8,698 | 7,518 | 8,160 | 8,764 | 8,244 | 8,319 | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | 0.7% | 62,337 | 61,876 | 63,171 | 62,557 | 62,870 | 63,080 | 67,952 | 67,098 | 67,984 | 67,492 | 68,407 | 60,878 | 55,934 | 59,741 | 61,627 | 59,146 | 63,210 | 62,837 | 63,675 | 64,305 | 65,355 |
Current Assets | 6.2% | 14,287 | 13,456 | 14,443 | 13,554 | 13,175 | 12,629 | 14,772 | 13,991 | 13,925 | 13,278 | 15,996 | 30,926 | 24,643 | 26,950 | 30,296 | 28,361 | 33,727 | 34,024 | 35,836 | 34,918 | 32,728 |
Cash Equivalents | 15.6% | 5,704 | 4,936 | 5,412 | 4,699 | 4,739 | 4,296 | 5,338 | 4,362 | 4,893 | 4,065 | 5,997 | 12,886 | 6,746 | 10,051 | 11,631 | 9,474 | 11,240 | 16,927 | 17,940 | 14,569 | 13,234 |
Inventory | 3.6% | 1,633 | 1,576 | 1,507 | 1,463 | 1,494 | 1,482 | 1,618 | 1,676 | 1,772 | 1,779 | 1,683 | 1,008 | 1,052 | 986 | 922 | 882 | 884 | 898 | 814 | 816 | 859 |
Net PPE | 1.1% | 5,540 | 5,479 | 5,475 | 5,349 | 5,299 | 5,253 | 5,121 | 5,037 | 4,996 | 4,990 | 4,967 | 4,810 | 4,653 | 4,564 | 4,502 | 4,377 | 4,249 | 4,116 | 4,006 | 3,791 | 3,659 |
Goodwill | 0% | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,332 | 8,332 | 8,334 | 8,334 | 8,108 | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 4,117 | 4,124 |
Current Liabilities | 32.6% | 13,964 | 10,528 | 11,237 | 10,423 | 9,220 | 8,558 | 11,610 | 10,245 | 10,214 | 9,705 | 11,397 | 9,509 | 10,564 | 8,879 | 9,759 | 9,567 | 8,961 | 9,397 | 10,605 | 10,116 | 10,912 |
LT Debt, Non Current | -7.6% | 21,209 | 22,956 | 22,957 | 22,953 | 25,195 | 25,183 | 25,179 | 25,175 | 27,914 | 27,907 | 28,645 | 27,792 | 21,103 | 22,098 | 22,094 | 22,090 | 24,084 | 24,080 | 24,574 | 24,570 | 26,062 |
Shareholder's Equity | 1.0% | 21,158 | 20,939 | 21,240 | 21,081 | 20,215 | 19,915 | 21,064 | 21,471 | 19,710 | 18,964 | 18,221 | 17,471 | 18,142 | 22,179 | 22,650 | 20,736 | 22,751 | 22,091 | 21,534 | 23,007 | 21,734 |
Retained Earnings | -0.6% | 15,138 | 15,223 | 15,687 | 15,756 | 15,117 | 14,986 | 16,324 | 16,903 | 15,392 | 14,821 | 14,381 | 13,709 | 14,445 | 18,709 | 19,388 | 17,616 | 19,829 | 19,326 | 19,024 | 20,706 | 19,825 |
Additional Paid-In Capital | 3.7% | 6,008 | 5,793 | 5,550 | 5,226 | 5,031 | 4,867 | 4,661 | 4,492 | 4,271 | 4,092 | 3,880 | 3,712 | 3,511 | 3,311 | 3,051 | 2,870 | 2,684 | 2,494 | 2,282 | 2,118 | 1,844 |
Shares Outstanding | -0.1% | 1,247 | 1,248 | 1,247 | 1,254 | 1,256 | 1,255 | 1,254 | 1,256 | 1,255 | 1,256 | 1,254 | 1,255 | 1,255 | 1,262 | 1,266 | 1,267 | 1,270 | 1,276 | 1,282 | 1,296 | 1,298 |
Minority Interest | -10.3% | -64.00 | -58.00 | -31.00 | -24.00 | -21.00 | -12.00 | -5.00 | 1.00 | 7.00 | 12.00 | 19.00 | 26.00 | 115 | 112 | 125 | 132 | 135 | 140 | 147 | 146 | 62.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | 6.0% | 9,512 | 8,976 | 9,072 | 9,710 | 10,100 | 10,614 | 11,384 | 10,095 | 9,092 | 9,342 | 8,168 | 8,832 | 9,227 | 9,003 | 9,144 | 8,909 | 8,476 | 7,707 | 8,400 | 8,808 | 9,290 |
Share Based Compensation | 4.9% | 705 | 672 | 637 | 622 | 625 | 626 | 635 | 637 | 639 | 641 | 643 | 639 | 628 | 634 | 636 | 654 | 690 | 768 | 845 | 1,004 | 919 |
Cashflow From Investing | -7.9% | -2,397 | -2,222 | -2,466 | -2,369 | -1,890 | -2,159 | -3,131 | -11,830 | -11,867 | -16,313 | -14,615 | -5,207 | -6,777 | -7,917 | -7,817 | -5,513 | -1,647 | 9,757 | 14,355 | 1,604 | -2,535 |
Cashflow From Financing | -1.6% | -6,179 | -6,081 | -6,469 | -6,857 | -8,266 | -8,194 | -8,877 | -6,804 | 847 | 904 | 770 | -257 | -6,896 | -7,879 | -7,634 | -8,408 | -8,794 | -8,089 | -12,318 | -7,301 | -2,230 |
Dividend Payments | 0.6% | 3,757 | 3,733 | 3,709 | 3,688 | 3,659 | 3,633 | 3,605 | 3,569 | 3,530 | 3,492 | 3,449 | 3,392 | 3,335 | 3,279 | 3,222 | 3,157 | 3,095 | 3,035 | 2,971 | 2,917 | 2,857 |
Buy Backs | 5.4% | 1,570 | 1,490 | 1,396 | 699 | 654 | 633 | 546 | 541 | 596 | 609 | 1,583 | 1,733 | 1,747 | 2,278 | 1,749 | 2,641 | 2,876 | 2,742 | 2,900 | 2,091 | 1,757 |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Revenues: | ||||
Total revenues | $ 6,599 | $ 6,260 | $ 12,951 | $ 12,850 |
Costs and expenses: | ||||
Cost of goods sold | 1,442 | 1,442 | 2,843 | 2,866 |
Research and development expenses | 1,407 | 1,102 | 2,854 | 2,280 |
Acquired in-process research and development expenses | 236 | 330 | 717 | 338 |
In-process research and development impairment | 0 | 0 | 0 | 2,700 |
Selling, general and administrative expenses | 1,849 | 1,357 | 3,168 | 2,440 |
Total costs and expenses | 4,934 | 4,231 | 9,581 | 10,624 |
Operating income | 1,665 | 2,029 | 3,370 | 2,226 |
Interest expense | (230) | (242) | (459) | (480) |
Other income (expense), net | 152 | (284) | (22) | (395) |
Income before income taxes | 1,588 | 1,503 | 2,888 | 1,351 |
Income tax expense | (549) | (368) | (865) | (204) |
Net income | 1,039 | 1,135 | 2,024 | 1,147 |
Net loss attributable to noncontrolling interest | 6 | 9 | 32 | 16 |
Net income attributable to Gilead | $ 1,045 | $ 1,144 | $ 2,055 | $ 1,163 |
Basic earnings per share attributable to Gilead (in dollars per share) | $ 0.84 | $ 0.91 | $ 1.65 | $ 0.93 |
Shares used in basic earnings per share attributable to Gilead calculation (in shares) | 1,249 | 1,256 | 1,249 | 1,255 |
Diluted earnings per share attributable to Gilead (in dollars per share) | $ 0.83 | $ 0.91 | $ 1.63 | $ 0.92 |
Shares used in diluted earnings per share attributable to Gilead calculation (in shares) | 1,258 | 1,260 | 1,260 | 1,261 |
Product sales | ||||
Revenues: | ||||
Total revenues | $ 6,564 | $ 6,138 | $ 12,870 | $ 12,672 |
Royalty, contract and other revenues | ||||
Revenues: | ||||
Total revenues | $ 35 | $ 122 | $ 81 | $ 178 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 5,704 | $ 5,412 |
Short-term marketable debt securities | 963 | 973 |
Accounts receivable, net | 4,229 | 4,777 |
Inventories | 1,633 | 1,507 |
Prepaid and other current assets | 1,757 | 1,774 |
Total current assets | 14,287 | 14,443 |
Property, plant and equipment, net | 5,540 | 5,475 |
Long-term marketable debt securities | 1,334 | 1,245 |
Intangible assets, net | 27,750 | 28,894 |
Goodwill | 8,314 | 8,314 |
Other long-term assets | 5,113 | 4,800 |
Total assets | 62,337 | 63,171 |
Current liabilities: | ||
Accounts payable | 622 | 905 |
Accrued rebates | 3,494 | 3,479 |
Other current liabilities | 5,810 | 4,580 |
Current portion of long-term debt and other obligations, net | 4,037 | 2,273 |
Total current liabilities | 13,964 | 11,237 |
Long-term debt, net | 21,209 | 22,957 |
Long-term income taxes payable | 2,610 | 3,916 |
Deferred tax liability | 2,106 | 2,673 |
Other long-term obligations | 1,354 | 1,179 |
Commitments and contingencies (Note 10) | ||
Stockholders’ equity: | ||
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding | 0 | 0 |
Common stock, par value $0.001 per share; 5,600 shares authorized; 1,247 shares issued and outstanding | 1 | 1 |
Additional paid-in capital | 6,008 | 5,550 |
Accumulated other comprehensive income | 10 | 2 |
Retained earnings | 15,138 | 15,687 |
Total Gilead stockholders’ equity | 21,158 | 21,240 |
Noncontrolling interest | (64) | (31) |
Total stockholders’ equity | 21,094 | 21,209 |
Total liabilities and stockholders’ equity | $ 62,337 | $ 63,171 |